Please login to the form below

Not currently logged in
Email:
Password:

Merck and Co

This page shows the latest Merck and Co news and features for those working in and with pharma, biotech and healthcare.

A look ahead to key trial readouts at ESMO

A look ahead to key trial readouts at ESMO

In immuno-oncology, this year’s offering includes a first showing for data in first-line advanced renal cell carcinoma for Merck KGaA/Pfizer’s Bavencio (avelumab) in the JAVELIN Renal ... Merck &Co/MSD – already dominating non-small cell lung

Latest news

  • Novartis wins key adjuvant Taf/Mek approval in Europe Novartis wins key adjuvant Taf/Mek approval in Europe

    Bristol-Myers Squibb’s Opdivo and Merck &Co/MSD’s Keytruda. ... Meanwhile, Merck filed an application for Keytruda in the US in June as an adjuvant therapy based on the KEYNOTE-054 trial.

  • Eisai’s Lenvima wins European liver cancer indication Eisai’s Lenvima wins European liver cancer indication

    Japanese pharma group Eisai and partner Merck &Co have received a nod from the European Commission (EC) to market its anti-cancer drug Lenvima to treat a certain type of liver ... Additionally, Lenvima also demonstrated statistically significant

  • Sanofi latest to reveal Brexit stockpiling of drugs Sanofi latest to reveal Brexit stockpiling of drugs

    AstraZeneca and MSD (Merck &Co in the US) have both said they are stockpiling in order to head off the threat of medicines shortages in the UK and the rest of ... More than 2, 600 medicines undergo at least one stage of manufacturing in the UK, and many

  • Alnylam’s amyloidosis drug heads latest crop of CHMP approvals Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

    failed trial in complicated urinary tract infections (cUTI) that pitted the drug against Merck &Co/MSD’s Infanz (ertapenem). ... The drug was originally developed by India’s Sun Pharma and is licensed to Merck &Co in the US, where it was approved in

  • Alnylam’s amyloidosis drug heads latest crop of CHMP approvals Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

    failed trial in complicated urinary tract infections (cUTI) that pitted the drug against Merck &Co/MSD’s Infanz (ertapenem). ... The drug was originally developed by India’s Sun Pharma and is licensed to Merck &Co in the US, where it was approved in

More from news
Approximately 46 fully matching, plus 448 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Checkpoint inhibitors – old and new. The first wave of checkpoint inhibitors targeting PD-(L) 1 and CTLA-4, from Bristol-Myers Squibb, Merck &Co, Roche, AstraZeneca and Merck KGaA/Pfizer, have ... Meanwhile, Incyte’s Merck &Co partnered IDO inhibitor

  • Advancing women in healthcare Advancing women in healthcare

    Taking on the mantle of HBA’s Woman of the Year 2018 is Julie Gerberding, Merck &Co’s chief patient officer, and head of global public policy and population health. ... She joined Merck &Co in 2009 and sees her role in promoting vaccines and

  • The good, the bad and the ugly The good, the bad and the ugly

    Beyond Pfizer, the biggest positive movers in the top 20 include Shire, Bayer and Merck &Co. ... 2020.”. Central Nervous System. 2017 was a quiet year in CNS. The most prominent growing companies were Merck &Co (49.8%), Takeda (39.1%) and Sumitomo

  • Deal Watch - May 2017 Deal Watch - May 2017

    More recent data reported in FiercePharma (1. st. May) shows Amgen has cash overseas of $34bn, Gilead $27bn and Merck &Co $22bn. ... It has signed deals with 10 companies in the last two years including Novartis, Genentech, Sanofi, Merck &Co and Lilly.

  • Deal Watch September 2016 Deal Watch September 2016

    Merck &Co has sold the US and Canadian rights for its Zontivity, or vorapaxar, to Aralez Pharmaceuticals in an asset purchase agreement worth $25m. ... 600. Verily / Sanofi. JV. Co-investment to form Onduo combining Sanofi's diabetes expertise with Verily

More from intelligence
Approximately 0 fully matching, plus 36 partially matching documents found.

Latest appointments

  • Weekly industry appointments Weekly industry appointments

    Laboratories and Merck &Co. ... to help take Abcam to the next stage in its development and growth.”.

  • Nabriva Therapeutics appoints chief medical officer Nabriva Therapeutics appoints chief medical officer

    Dr Schranz joins Nabriva from Irish biopharma Shire, with nearly two decades of experience in clinical development and medical affairs. ... Her career has seen her hold positions at Shire, ViroPharma, Pfizer, GlaxoSmithKline and Merck &Co.

  • Hansa Medical poaches Vifor Pharma’s CEO Hansa Medical poaches Vifor Pharma’s CEO

    Hansa Medical poaches Vifor Pharma’ s CEO. Søren Tulstrup becomes the Swedish biopharma’s CEO and president. ... Additionally, Tulstrup has served as CEO of Santaris Pharma, now part of Roche, and in several senior commercial roles within Merck &Co

  • Astellas promotes Anthony Fiordaliso to VP, Americas finance Astellas promotes Anthony Fiordaliso to VP, Americas finance

    He has been with the pharma company since 2010, when he joined from Schering-Plough (now part of Merck &Co) and subsequently held positions of increasing responsibility. ... In his new role Fiordaliso will report to Stephen Knowles, senior vice president

  • Intellia Therapeutics appoints Dr Moncef Slaoui and Dr Frank Verwiel Intellia Therapeutics appoints Dr Moncef Slaoui and Dr Frank Verwiel

    Intellia Therapeutics appoints Dr Moncef Slaoui and Dr Frank Verwiel. They will join the board of directors. ... Verwiel has also served at Merck &Co, where he was vice president and was general manager at Merck Sharpe Dohme’s operations in the

More from appointments
Approximately 4 fully matching, plus 32 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics